Results 191 to 200 of about 2,893,970 (365)

The pharmacological properties of 2-[3-[3-(1-piperidinylmethyl) phenoxy]-1-propylamino]-5-amino-1,3,4-thiadiazole hydrochloride (TAS), a new histamine H2-receptor antagonist : comparison with ranitidine and cimetidine (II).

, 1985
Hitoshi Aoki, Yoshihiro TSURIYA, Hidehiko Matsukawa, Masayuki Seya   +3 more
openalex   +1 more source

ESTIMATION OF pK_B VALUES FOR HISTAMINE H₂‐RECEPTOR ANTAGONISTS USING AN in vitro ACID SECRETION ASSAY [PDF]

, 1980
James A. Angus, J.W. Black, M. Stone
openalex   +1 more source

Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist

Acta Neurologica Scandinavica, Supplementum, 2013
Michael A. Rogawski, Takahisa Hanada
semanticscholar   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study. [PDF]

Pharmaceuticals (Basel)
Francke K, Baumann S, Gashaw I, Klein S, Rohde B, Zolk O, Fischer OM, Friedrich C.   +7 more
europepmc   +1 more source

Comparison of the Effect of Several Gonadotropin Releasing Hormone Antagonists on Luteinizing Hormone Secretion, Receptor Binding and Ovulation [PDF]

, 1983
Catherine Rivier, Jean Rivier, Marilyn H. Perrin, Wylie Vale   +3 more
openalex   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). [PDF]

Pragmat Obs Res
Richard EL, Stephenson JJ, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG.   +10 more
europepmc   +1 more source

Comparison of levocabastine, a new selective H1‐receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen. [PDF]

, 1986
M Kolly, Alain Pécoud
openalex   +1 more source

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

Journal of Nuclear Medicine, 2014
D. Wild, M. Fani, Richard Fischer, L. Del Pozzo, F. Kaul, S. Krebs, Richard Fischer, J. Rivier, J. Reubi, H. Maecke, W. Weber   +10 more
semanticscholar   +1 more source